dc.contributor.author
Lachmann, Gunnar
dc.contributor.author
Knaak, Cornelia
dc.contributor.author
Haefen, Clarissa von
dc.contributor.author
Paeschke, Nadine
dc.contributor.author
Meisel, Christian
dc.contributor.author
Nyvlt, Peter
dc.contributor.author
Schuster, Friederike S.
dc.contributor.author
Piper, Sophie K.
dc.contributor.author
Kruppa, Jochen
dc.contributor.author
Vorderwülbecke, Gerald
dc.contributor.author
Balzer, Felix
dc.contributor.author
La Rosée, Paul
dc.contributor.author
Schenk, Thomas
dc.contributor.author
Unterwalder, Nadine
dc.contributor.author
Kölsch, Uwe
dc.contributor.author
Lachmann, Nils
dc.contributor.author
Akyüz, Levent
dc.contributor.author
Brunkhorst, Frank M.
dc.contributor.author
Volk, Hans-Dieter
dc.contributor.author
Keh, Didier
dc.contributor.author
Spies, Claudia
dc.date.accessioned
2019-11-11T15:40:07Z
dc.date.available
2019-11-11T15:40:07Z
dc.identifier.uri
https://refubium.fu-berlin.de/handle/fub188/25907
dc.identifier.uri
http://dx.doi.org/10.17169/refubium-25665
dc.description.abstract
INTRODUCTION: Haemophagocytic lymphohistiocytosis (HLH) in adults is characterised by toxic immune activation and a sepsis-like syndrome, leading to high numbers of undiagnosed cases and mortality rates of up to 68%. Early diagnosis and specific immune suppressive treatment are mandatory to avoid fatal outcome, but the diagnostic criteria (HLH-2004) are adopted from paediatric HLH and have not been validated in adults. Experimental studies suggest biomarkers to sufficiently diagnose HLH. However, biomarkers for the diagnosis of adult HLH have not yet been investigated.
METHODS AND ANALYSIS: The HEMICU (Diagnostic biomarkers for adult haemophagocytic lymphohistiocytosis in critically ill patients) study aims to estimate the incidence rate of adult HLH among suspected adult patients in intensive care units (ICUs). Screening for HLH will be performed in 16 ICUs of Charité - Universitätsmedizin Berlin. The inclusion criteria are bicytopaenia, hyperferritinaemia (≥500 µg/L), fever or when HLH is suspected by the clinician. Over a period of 2 years, we expect inclusion of about 100 patients with suspected HLH. HLH will be diagnosed if at least five of the HLH-2004 criteria are fulfilled, together with an expert review; all other included patients will serve as controls. Second, a panel of potential biomarker candidates will be explored. DNA, plasma and serum will be stored in a biobank. The primary endpoint of the study is the incidence rate of adult HLH among suspected adult patients during ICU stay. Out of a variety of measured biomarkers, this study furthermore aims to find highly potential biomarkers for the diagnosis of adult HLH in ICU. The results of this study will contribute to improved recognition and patient outcome of adult HLH in clinical routine.
en
dc.rights.uri
https://creativecommons.org/licenses/by-nc/4.0/
dc.subject
intensive care unit
en
dc.subject
haemophagocytic lymphohistiocytosis
en
dc.subject
haemophagocytic syndrome
en
dc.subject
macrophage activation syndrome
en
dc.subject.ddc
600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit::610 Medizin und Gesundheit
dc.title
Diagnostic biomarkers for adult haemophagocytic lymphohistiocytosis in critically ill patients (HEMICU): a prospective observational study protocol
dc.type
Wissenschaftlicher Artikel
dcterms.bibliographicCitation.articlenumber
e032695
dcterms.bibliographicCitation.doi
10.1136/bmjopen-2019-032695
dcterms.bibliographicCitation.journaltitle
BMJ Open
dcterms.bibliographicCitation.number
10
dcterms.bibliographicCitation.originalpublishername
BMJ Publishing Group
dcterms.bibliographicCitation.volume
9
refubium.affiliation
Charité - Universitätsmedizin Berlin
refubium.resourceType.isindependentpub
no
dcterms.accessRights.openaire
open access
dcterms.bibliographicCitation.pmid
31666276
dcterms.isPartOf.eissn
2044-6055